Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Corso

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Haematologica|May 13, 2010
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaJean-Luc Harousseau, Meletios A Dimopoulos, Michael Wang, et al.
Leukemia & Lymphoma|December 17, 2009
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myelomaAlessandro Corso, Luciana Barbarano, Silvia Mangiacavalli, et al.
Transplant Immunology|October 31, 2025
Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols?Viola Chiavetta, Martina Soldarini, Anna Maria Cafro, et al.
British Journal of Haematology|January 4, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapseVittorio Montefusco, Alessandro Corso, Monica Galli, et al.
Oncology and Therapy|February 25, 2021
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and RussiaGordon Cook, Alessandro Corso, Matthew Streetly, et al.
Blood|January 29, 2013
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasmsMarzia Varettoni, Luca Arcaini, Silvia Zibellini, et al.
Leukemia & Lymphoma|July 22, 2016
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II studySamantha Pozzi, Massimo Gentile, Stefano Sacchi, et al.
Blood|January 29, 2017
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicityLaura Oliva, Ugo Orfanelli, Massimo Resnati, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
Leukemia|September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseMeletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Haematologica|May 13, 2010
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaJean-Luc Harousseau, Meletios A Dimopoulos, Michael Wang, et al.
Leukemia & Lymphoma|December 17, 2009
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myelomaAlessandro Corso, Luciana Barbarano, Silvia Mangiacavalli, et al.
Transplant Immunology|October 31, 2025
Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols?Viola Chiavetta, Martina Soldarini, Anna Maria Cafro, et al.
British Journal of Haematology|January 4, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapseVittorio Montefusco, Alessandro Corso, Monica Galli, et al.
Oncology and Therapy|February 25, 2021
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and RussiaGordon Cook, Alessandro Corso, Matthew Streetly, et al.
Blood|January 29, 2013
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasmsMarzia Varettoni, Luca Arcaini, Silvia Zibellini, et al.
Leukemia & Lymphoma|July 22, 2016
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II studySamantha Pozzi, Massimo Gentile, Stefano Sacchi, et al.
Blood|January 29, 2017
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicityLaura Oliva, Ugo Orfanelli, Massimo Resnati, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
Leukemia|September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseMeletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
Pageof 6